Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

BACKGROUND: The Betaferon/Betaseron in newly emerging multiple sclerosis for initial treatment (BENEFIT) trial investigated the effect of treatment with interferon beta-1b after a clinically isolated syndrome. The 5-year active treatment extension compares the effects of early and delayed treatment...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The Lancet Neurology 2009-11, Vol.8 (11), p.987-997
Hauptverfasser:	Kappos, Ludwig, Freedman, Mark, Polman, Chris, Edan, Gilles, Hartung, Hans-Peter, Miller, David, Montalban, Xavier, Barkhof, Frederik, Radü, Ernst-Wilhelm, Metzig, Carola, Bauer, Lars, Lanius, Vivian, Sandbrink, Rupert, Pohl, Christoph, BENEFIT study group
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!